Research programme: cancer therapeutics - Mateon TherapeuticsAlternative Names: KGP-156; KGP-18; KGP-94
Latest Information Update: 12 Oct 2016
At a glance
- Originator Baylor University; OXiGENE
- Developer Mateon Therapeutics
- Class Benzophenones; Small molecules; Thiosemicarbazones
- Mechanism of Action Cathepsin L inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer